Loading
A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib is a phase 3 interventional study registered as NCT04421963 by AstraZeneca, with 185 participants enrolled, started 2020-08-04 and due to reach its primary completion in 2027-04-06. Interventions recorded: Olaparib. Conditions listed: Ovarian Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/